Over the past 30 years, studies have shown that the prevalence of diabetes in China was gradually rising trend.  At present, China faces new problems: the world's largest diabetes populations.  China now has 92 million diabetic patients.  The World Health Organization estimated in 2006 to 2015, diabetes, heart disease and stroke will cost China 558 billion U.S. dollars.

"With this new product we will broaden our portfolio of innovative insulin support technologies and strengthen our position to be a new player in the diabetes care business," said Scott Sand, CEO.  Sand further stated, "We are already manufacturing respiratory products and the company is ISO certified with a DHS license to manufacture medical product.  We anticipate starting right away to design the tooling and production processes.  The device is mold injected and can be massed produced very easily.  Product pricing is expected to be at $45 per unit with COGS at $8 per unit.  The margins and projected gross profits are generous."

Source : Ingen Files